Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

198 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Relationships of HDL cholesterol, ApoA-I, and ApoA-II with homocysteine and creatinine in patients with type 2 diabetes treated with fenofibrate.
Taskinen MR, Sullivan DR, Ehnholm C, Whiting M, Zannino D, Simes RJ, Keech AC, Barter PJ; FIELD study investigators. Taskinen MR, et al. Among authors: keech ac. Arterioscler Thromb Vasc Biol. 2009 Jun;29(6):950-5. doi: 10.1161/ATVBAHA.108.178228. Epub 2009 Mar 26. Arterioscler Thromb Vasc Biol. 2009. PMID: 19325138 Clinical Trial.
Long-term effects of fenofibrate on carotid intima-media thickness and augmentation index in subjects with type 2 diabetes mellitus.
Hiukka A, Westerbacka J, Leinonen ES, Watanabe H, Wiklund O, Hulten LM, Salonen JT, Tuomainen TP, Yki-Järvinen H, Keech AC, Taskinen MR. Hiukka A, et al. Among authors: keech ac. J Am Coll Cardiol. 2008 Dec 16;52(25):2190-7. doi: 10.1016/j.jacc.2008.09.049. J Am Coll Cardiol. 2008. PMID: 19095138 Free article. Clinical Trial.
Incidence and predictors of silent myocardial infarction in type 2 diabetes and the effect of fenofibrate: an analysis from the Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Burgess DC, Hunt D, Li L, Zannino D, Williamson E, Davis TM, Laakso M, Kesäniemi YA, Zhang J, Sy RW, Lehto S, Mann S, Keech AC. Burgess DC, et al. Among authors: keech ac. Eur Heart J. 2010 Jan;31(1):92-9. doi: 10.1093/eurheartj/ehp377. Epub 2009 Sep 29. Eur Heart J. 2010. PMID: 19797259 Clinical Trial.
Impact of metabolic syndrome and its components on cardiovascular disease event rates in 4900 patients with type 2 diabetes assigned to placebo in the FIELD randomised trial.
Scott R, Donoghoe M, Watts GF, O'Brien R, Pardy C, Taskinen MR, Davis TM, Colman PG, Manning P, Fulcher G, Keech AC; FIELD Study Investigators. Scott R, et al. Among authors: keech ac. Cardiovasc Diabetol. 2011 Nov 21;10:102. doi: 10.1186/1475-2840-10-102. Cardiovasc Diabetol. 2011. PMID: 22104275 Free PMC article. Clinical Trial.
Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment: the FIELD Study.
Ting RD, Keech AC, Drury PL, Donoghoe MW, Hedley J, Jenkins AJ, Davis TM, Lehto S, Celermajer D, Simes RJ, Rajamani K, Stanton K; FIELD Study Investigators. Ting RD, et al. Among authors: keech ac. Diabetes Care. 2012 Feb;35(2):218-25. doi: 10.2337/dc11-1109. Epub 2011 Dec 30. Diabetes Care. 2012. PMID: 22210576 Free PMC article. Clinical Trial.
Effects of fenofibrate on cardiovascular events in patients with diabetes, with and without prior cardiovascular disease: The Fenofibrate Intervention and Event Lowering in Diabetes (FIELD) study.
Tonkin A, Hunt D, Voysey M, Kesäniemi A, Hamer A, Waites J, Mahar L, Mann S, Glasziou P, Forder P, Simes J, Keech AC; FIELD Study Investigators. Tonkin A, et al. Among authors: keech ac. Am Heart J. 2012 Mar;163(3):508-14. doi: 10.1016/j.ahj.2011.12.004. Am Heart J. 2012. PMID: 22424024 Free article. Clinical Trial.
198 results